{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:01:07Z","timestamp":1784858467136,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100014476","name":"Pfizer Netherlands","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","award":["LSHM17074"],"award-info":[{"award-number":["LSHM17074"]}],"id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-026-03833-7","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:58:19Z","timestamp":1779929899000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating immune cell biomarkers in Psoriatic Arthritis: associations with clinical manifestations and treatment response in the TOFA-PREDICT trial"],"prefix":"10.1186","volume":"28","author":[{"given":"F. T.","family":"Perton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. N.","family":"Pouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Spierings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. N.","family":"Kors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. N.","family":"Concepcion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. P. J.","family":"Bekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. E.","family":"Vonkeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. C.","family":"Mooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. G.","family":"Schipper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Vreugdenhil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"TOFA-PREDICT author group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavish J.","family":"Bhansing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radjesh J.","family":"Bisoendial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra T.A.","family":"van Bijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenny","family":"van Bon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoaneta C.","family":"Comarniceanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazira","family":"Jahangier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim L.T.A.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvana W.","family":"Kadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc R.","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arno W. R.","family":"van Kuijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmerik F.A.","family":"Leijten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasti C.","family":"Mooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia G.","family":"Schipper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid M.","family":"van Tubergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald E.","family":"Vonkeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone A.","family":"Vreugdenhil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siska","family":"Wijngaarden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. C.","family":"Mastbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. M. J.","family":"Welsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"issue":"10136","key":"3833_CR1","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273\u201384.","journal-title":"Lancet"},{"issue":"1","key":"3833_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3899\/jrheum.220315","volume":"50","author":"YY Leung","year":"2023","unstructured":"Leung YY, Korotaeva TV, Candia L, Pedersen SJ, Bautista Molano W, Ruderman EM, et al. Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. J Rheumatol. 2023;50(1):119\u201330.","journal-title":"J Rheumatol"},{"issue":"7","key":"3833_CR3","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1093\/rheumatology\/keae006","volume":"63","author":"CE Gollins","year":"2024","unstructured":"Gollins CE, Vincent R, Fahy C, McHugh N, Brooke M, Tillett W. Effectiveness of sequential lines of biologic and targeted small-molecule drugs in psoriatic arthritis: a systematic review. Rheumatology (Oxford). 2024;63(7):1790\u2013802.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"3833_CR4","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/ard-2024-225534","volume":"83","author":"A Kerschbaumer","year":"2024","unstructured":"Kerschbaumer A, Smolen JS, Ferreira RJO, Bertheussen H, Baraliakos X, Aletaha D, et al. Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2024;83(6):760\u201374.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3833_CR5","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706\u201319.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"3833_CR6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465\u201379.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"3833_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019;71(1):5\u201332.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"3833_CR8","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1136\/ard.2011.150938","volume":"70","author":"DD Gladman","year":"2011","unstructured":"Gladman DD, Thavaneswaran A, Chandran V, Cook RJ. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis. 2011;70(12):2152\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"3833_CR9","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1136\/annrheumdis-2012-202608","volume":"72","author":"W Tillett","year":"2013","unstructured":"Tillett W, Jadon D, Shaddick G, Cavill C, Korendowych E, de Vries CS, et al. Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. Ann Rheum Dis. 2013;72(8):1358\u201361.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"3833_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-064338","volume":"12","author":"NJ Kleinrensink","year":"2022","unstructured":"Kleinrensink NJ, Perton FT, Pouw JN, Vincken NLA, Hartgring SAY, Jansen MP, et al. TOFA-PREDICT study protocol: a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in psoriatic arthritis (PsA). BMJ Open. 2022;12(10):e064338.","journal-title":"BMJ Open"},{"issue":"1","key":"3833_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13075-025-03660-2","volume":"27","author":"FT Perton","year":"2025","unstructured":"Perton FT, Bentvelzen MLM, Fadaei S, Pouw JN, Spierings J, Vonkeman HE, et al. The development of a clinical prediction model for response to methotrexate, tofacitinib, and etanercept in patients with Psoriatic Arthritis. Arthritis Res Ther. 2025;27(1):197.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"3833_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69(1):48\u201353.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3833_CR13","first-page":"238","volume":"157","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978;157(4):238\u201344.","journal-title":"Dermatologica"},{"issue":"5","key":"3833_CR14","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.23568","volume":"59","author":"PJ Healy","year":"2008","unstructured":"Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum. 2008;59(5):686\u201391.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"3833_CR15","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/ard.2009.122259","volume":"69","author":"M Schoels","year":"2010","unstructured":"Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis. 2010;69(8):1441\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"3833_CR16","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/art.41652","volume":"73","author":"EF Leijten","year":"2021","unstructured":"Leijten EF, van Kempen TS, Olde Nordkamp MA, Pouw JN, Kleinrensink NJ, Vincken NL, et al. Tissue-Resident Memory CD8+ T Cells From Skin Differentiate Psoriatic Arthritis From Psoriasis. Arthritis Rheumatol. 2021;73(7):1220\u201332.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"3833_CR17","doi-asserted-by":"publisher","first-page":"20675","DOI":"10.1038\/s41598-022-24924-w","volume":"12","author":"JN Pouw","year":"2022","unstructured":"Pouw JN, Olde Nordkamp MAM, van Kempen T, Concepcion AN, van Laar JM, van Wijk F, et al. Regulatory T cells in psoriatic arthritis: an IL-17A-producing, Foxp3(int)CD161 + RORgammat + ICOS + phenotype, that associates with the presence of ADAMTSL5 autoantibodies. Sci Rep. 2022;12(1):20675.","journal-title":"Sci Rep"},{"key":"3833_CR18","unstructured":"A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2018. Available online at https:\/\/www.R-project.org\/.\u00a0"},{"issue":"1","key":"3833_CR19","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.1038\/s41598-023-31990-1","volume":"13","author":"R Fedr","year":"2023","unstructured":"Fedr R, Kahounov\u00e1 Z, Rem\u0161\u00edk J, Reiterov\u00e1 M, Kalina T, Sou\u010dek K. Variability of fluorescence intensity distribution measured by flow cytometry is influenced by cell size and cell cycle progression. Sci Rep. 2023;13(1):4889.","journal-title":"Sci Rep"},{"issue":"9","key":"3833_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-078539","volume":"13","author":"A Ooms","year":"2023","unstructured":"Ooms A, Al-Mossawi H, Bennett L, Bogale M, Bowness P, Francis A, et al. Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritis. BMJ Open. 2023;13(9):e078539.","journal-title":"BMJ Open"},{"key":"3833_CR21","doi-asserted-by":"crossref","unstructured":"Grohmann T, Vivekanantham A, Coates LC, Pennington S, FitzGerald O. Clinical, genetic and omics-based biomarkers that might support the identification of the development of psoriatic arthritis in individuals with psoriasis: a narrative review of the literature. RMD Open. 2024;10(4):e004176.","DOI":"10.1136\/rmdopen-2024-004176"},{"issue":"2","key":"3833_CR22","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/rheumatology\/key069","volume":"58","author":"I Miyagawa","year":"2019","unstructured":"Miyagawa I, Nakayamada S, Nakano K, Kubo S, Iwata S, Miyazaki Y, et al. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology (Oxford). 2019;58(2):336\u201344.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"3833_CR23","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/bjd.18001","volume":"181","author":"K Reich","year":"2019","unstructured":"Reich K, Reich JLK, Falk TM, Blodorn-Schlicht N, Mrowietz U, von Kiedrowski R, et al. Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways. Br J Dermatol. 2019;181(4):859\u201362.","journal-title":"Br J Dermatol"},{"key":"3833_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076343","author":"M Skougaard","year":"2023","unstructured":"Skougaard M, Ditlev SB, S\u00f8ndergaard MF, Kristensen LE. Cytokine signatures in psoriatic arthritis patients indicate different phenotypic traits comparing responders and non-responders of IL-17A and TNF\u03b1 inhibitors. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24076343.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"3833_CR25","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/jid.2011.139","volume":"131","author":"HJ Bovenschen","year":"2011","unstructured":"Bovenschen HJ, van de Kerkhof PC, van Erp PE, Woestenenk R, Joosten I, Koenen HJ. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol. 2011;131(9):1853\u201360.","journal-title":"J Invest Dermatol"},{"issue":"9","key":"3833_CR26","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s10067-015-3002-2","volume":"34","author":"U Fiocco","year":"2015","unstructured":"Fiocco U, Martini V, Accordi B, Caso F, Costa L, Oliviero F, et al. Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clin Rheumatol. 2015;34(9):1571\u201380.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"3833_CR27","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1111\/ajd.12561","volume":"59","author":"L Han","year":"2018","unstructured":"Han L, Sugiyama H, Zhang Q, Yan K, Fang X, McCormick TS, et al. Phenotypical analysis of ectoenzymes CD39\/CD73 and adenosine receptor 2A in CD4(+) CD25(high) Foxp3(+) regulatory T-cells in psoriasis. Australas J Dermatol. 2018;59(1):e31\u20138.","journal-title":"Australas J Dermatol"},{"issue":"1","key":"3833_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.clim.2013.06.007","volume":"149","author":"DC Soler","year":"2013","unstructured":"Soler DC, Sugiyama H, Young AB, Massari JV, McCormick TS, Cooper KD. Psoriasis patients exhibit impairment of the high potency CCR5(+) T regulatory cell subset. Clin Immunol. 2013;149(1):111\u20138.","journal-title":"Clin Immunol"},{"issue":"1","key":"3833_CR29","doi-asserted-by":"publisher","first-page":"164","DOI":"10.4049\/jimmunol.174.1.164","volume":"174","author":"H Sugiyama","year":"2005","unstructured":"Sugiyama H, Gyulai R, Toichi E, Garaczi E, Shimada S, Stevens SR, et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol. 2005;174(1):164\u201373.","journal-title":"J Immunol"},{"issue":"1","key":"3833_CR30","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s42003-020-1097-8","volume":"3","author":"R Arroyo Hornero","year":"2020","unstructured":"Arroyo Hornero R, Georgiadis C, Hua P, Trzupek D, He LZ, Qasim W, et al. CD70 expression determines the therapeutic efficacy of expanded human regulatory T cells. Commun Biol. 2020;3(1):375.","journal-title":"Commun Biol"},{"key":"3833_CR31","doi-asserted-by":"crossref","unstructured":"Remedios KA, Zirak B, Sandoval PM, Lowe MM, Boda D, Henley E, et al. The TNFRSF members CD27 and OX40 coordinately limit T(H)17 differentiation in regulatory T cells. Sci Immunol. 2018;3(30):eaau2042.","DOI":"10.1126\/sciimmunol.aau2042"},{"key":"3833_CR32","doi-asserted-by":"crossref","unstructured":"Kim J, Bissonnette R, Lee J, Correa da Rosa J, Su\u00e1rez-Fari\u00f1as M, Lowes MA, et al. The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but\u00a0with Key Differences in Immune Regulatory Genes. J Invest Dermatol. 2016;136(11):2173\u201382.","DOI":"10.1016\/j.jid.2016.04.032"},{"issue":"1","key":"3833_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.108059","volume":"301","author":"T McTaggart","year":"2025","unstructured":"McTaggart T, Lim JX, Smith KJ, Heaney B, McDonald D, Hulme G, et al. Deep phenotyping of T regulatory cells in psoriatic arthritis highlights targetable mechanisms of disease. J Biol Chem. 2025;301(1):108059.","journal-title":"J Biol Chem"},{"issue":"2","key":"3833_CR34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nm0202-157","volume":"8","author":"B Homey","year":"2002","unstructured":"Homey B, Alenius H, M\u00fcller A, Soto H, Bowman EP, Yuan W, et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med. 2002;8(2):157\u201365.","journal-title":"Nat Med"},{"key":"3833_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.618897","volume":"11","author":"Y Tokura","year":"2020","unstructured":"Tokura Y, Phadungsaksawasdi P, Kurihara K, Fujiyama T, Honda T. Pathophysiology of Skin Resident Memory T Cells. Front Immunol. 2020;11:618897.","journal-title":"Front Immunol"},{"key":"3833_CR36","doi-asserted-by":"crossref","unstructured":"Eder L, Dang S, Caucheteux SM, Li X, Thib S, Ganatra D, et al. CD3+ immune cell endotypes are associated with PsA disease phenotype and response to advanced therapy: an integrated mass cytometry and proteomics cohort study. Ann Rheum Dis. 2025:457\u201366.","DOI":"10.1016\/j.ard.2025.10.011"},{"issue":"6","key":"3833_CR37","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/sji.12114","volume":"78","author":"JH Eysteinsd\u00f3ttir","year":"2013","unstructured":"Eysteinsd\u00f3ttir JH, Sigurgeirsson B, \u00d3lafsson JH, Fridriksson T, Agnarsson BA, Dav\u00ed\u00f0sson S, et al. The role of Th17\/Tc17 peripheral blood T cells in psoriasis and their positive therapeutic response. Scand J Immunol. 2013;78(6):529\u201337.","journal-title":"Scand J Immunol"},{"issue":"2","key":"3833_CR38","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1046\/j.1365-2249.2001.01688.x","volume":"126","author":"H Sigmundsd\u00f3ttir","year":"2001","unstructured":"Sigmundsd\u00f3ttir H, Gudj\u00f3nsson JE, J\u00f3nsd\u00f3ttir I, L\u00fadv\u00edksson BR, Valdimarsson H. The frequency of CLA+ CD8+ T cells in the blood of psoriasis patients correlates closely with the severity of their disease. Clin Exp Immunol. 2001;126(2):365\u20139.","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"3833_CR39","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.jaci.2020.05.044","volume":"147","author":"C Li","year":"2021","unstructured":"Li C, Xu M, Coyne J, Wang WB, Davila ML, Wang Y, et al. Psoriasis-associated impairment of CCL27\/CCR10-derived regulation leads to IL-17A\/IL-22-producing skin T-cell overactivation. J Allergy Clin Immunol. 2021;147(2):759-63.e9.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-026-03833-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03833-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03833-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:09:21Z","timestamp":1784855361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-026-03833-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3833"],"URL":"https:\/\/doi.org\/10.1186\/s13075-026-03833-7","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Reported in open protocol publication [\n                      \n                      ].","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HEV: paid consultant for Abbvie, Novartis, Pfizer, UCB, Johnson and Johnson. Financial grants from (pharmaceutical) companies: Galapagos and Boehringer Ingelheim. AWRVK: Paid consultant for Janssen, Novartis and UCB. Financial grants from Novartis and UCB.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"145"}}